Vertex Pharmaceuticals is set to acquire Crinetics Pharmaceuticals for $10 billion, the companies announced. The deal gives Vertex access to a drug for a rare endocrine disorder, marking a significant expansion of its pipeline.
The acquisition comes amid a surge in biotech M&A activity. For Vertex, known for its cystic fibrosis treatments, this move diversifies its portfolio into endocrine diseases, a high-value niche market.
Financial terms were disclosed as $10 billion, based on the announcement. No further financing details or expected closing date were provided in the source.
The purchase strengthens Vertex's drug development capacity while reducing its reliance on a single therapeutic area. Shareholders of both firms are expected to vote on the transaction in coming months.
Some analysts caution that integration risks and regulatory hurdles could delay the deal, though no specific concerns were cited in the announcement.